scroll to top
Loading icon
0

Mobile Menu

Header Layout

EBSCO Auth Banner

Let's find your institution. Click here.

Page title

Advanced Search Results For "sars-cov-2"

1 - 10 of 258,715 results for
 "sars-cov-2"
Results per page:

Antibody Responses after Two Doses of COVID-19 mRNA Vaccine in Dialysis and Kidney Transplantation Patients Recovered from SARS-CoV-2 Infection.

Publication Type:Academic Journal

Source(s):Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2022 Jul 03; Vol. 58 (7). Date of Electronic Publication: 2022 Jul 03.

Abstract:Background and Objectives: Hemodialysis patients (HD) and kidney transplant recipients (KTRs) have been heavily impacted by COVID-19, showing increased risk of infection, worse clinical outcomes, and higher mortality rates than the general population. ...

View details

Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.

Publication Type:Academic Journal

Source(s):The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2022 Jun; Vol. 149 (6), pp. 1949-1957. Date of Electronic Publication: 2022 Apr 11.

Abstract:Background: Patients with inborn errors of immunity (IEI) are at increased risk of severe coronavirus disease-2019 (COVID-19). Effective vaccination against COVID-19 is therefore of great importance in this group, but little is known about the immunoge...

View details

Lymphohistiocytic Myocarditis Possibly Due to Moderna mRNA-1273 Vaccine.

Publication Type:Academic Journal

Source(s):American journal of clinical pathology [Am J Clin Pathol] 2022 Aug 04; Vol. 158 (2), pp. 167-172.

Abstract:Objectives: Despite the clear benefits of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in mitigating the impact of the coronavirus disease 2019 pandemic, there are emerging reports of postvaccination myocarditis, the majorit...

View details

Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.

Publication Type:Academic Journal

Source(s):Neurology(R) neuroimmunology & neuroinflammation [Neurol Neuroimmunol Neuroinflamm] 2022 Jun 21; Vol. 9 (4). Date of Electronic Publication: 2022 Jun 21 (Print Publication: 2022).

Abstract:Background and Objectives: Evidence regarding the safety and efficacy of messenger RNA (mRNA) vaccines in patients with myasthenia gravis (MG) after immunosuppressive therapies is scarce. Our aim is to determine whether the mRNA-1273 vaccine is safe an...

View details

Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies.

Publication Type:Academic Journal

Source(s):Frontiers in immunology [Front Immunol] 2022 Jun 16; Vol. 13, pp. 864718. Date of Electronic Publication: 2022 Jun 16 (Print Publication: 2022).

Abstract:mRNA based vaccines against COVID-19 have proven most successful at keeping SARS-CoV-2 pandemic at bay in many countries. Recently, there is an increased interest in heterologous prime-boost vaccination strategies for COVID-19 to maintain antibody resp...

View details

Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan.

Publication Type:Academic Journal

Source(s):Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [J Clin Virol] 2022 Jun; Vol. 150-151, pp. 105156. Date of Electronic Publication: 2022 Apr 06.

Abstract:Background: In Taiwan, the vaccination program started in March 2021, with ChAdOx1-S being the first available WHO-approved COVID-19 vaccine, followed by Moderna vaccine. This study aimed to investigate the immunogenicity and safety of homologous and h...

View details

Sensitization to trometamol in patients with delayed local reactions after administration of the Moderna mRNA-1273 vaccine against SARS-CoV-2.

Publication Type:Academic Journal

Source(s):The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2022 Aug; Vol. 10 (8), pp. 2166-2168.e1. Date of Electronic Publication: 2022 May 03.

View details

Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine.

Publication Type:Academic Journal

Source(s):American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2022 Aug; Vol. 22 (8), pp. 2089-2093. Date of Electronic Publication: 2022 Mar 21.

Abstract:The SARS-CoV-2 virus Omicron variant has now supplanted wild-type virus as the dominant circulating strain globally. Three doses of mRNA COVID-19 vaccine are recommended for transplant recipients as their primary vaccine series. However, the immunogeni...

View details

Immune Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Liver Transplant Recipients.

Publication Type:Report

Source(s):Transplantation [Transplantation] 2022 Jul 01; Vol. 106 (7), pp. e341-e342. Date of Electronic Publication: 2022 Mar 23.

View details

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.

Publication Type:Academic Journal

Source(s):Nature communications [Nat Commun] 2022 Jun 02; Vol. 13 (1), pp. 3082. Date of Electronic Publication: 2022 Jun 02.

Abstract:SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 vaccines against BA.1 and BA.2 i...

View details

banner_970x250 (970x250)

sponsored